seroprevalence

Latest findings reveal few Canadian adults have antibodies to SARS-Cov-2

Canadian Blood Services and the CITF’s collaborative nine-province SARS-CoV-2 seroprevalence study for October thru November suggests that 1.5 per cent of healthy Canadians had been exposed to SARS-CoV-2. The highest levels were recorded in Western Canada but mass national vaccination remains only route to achieving herd immunity.

2021-02-25T18:49:48-05:00January 25, 2021|Media Releases, Seroprevalence studies|

The COVENANT Study: COVID-19 Cohort Study of People Experiencing Homelessness in Toronto

COVID-19 poses a serious health threat to people experiencing homelessness. Homelessness puts people at high risk during the COVID-19 pandemic, as shelters are an ideal environment for the transmission of SARS-CoV-2, the virus that causes COVID-19. More than 235,000 Canadians experience homelessness every year. Recruitment starts soon for the COVENANT study, which will provide [...]

2021-02-26T11:49:31-05:00December 10, 2020|Media Releases|

Two studies will help determine whether health care workers in Canada are at higher risk of contracting SARS-CoV-2

Preliminary, non-peer reviewed results suggest that in phase 1 of a study on healthcare workers led by Dr. Nicola Cherry at the University of Alberta, rates of infection were higher in physicians than in other HCWs and higher in Quebec physicians than among physicians in Alberta.

2021-02-25T17:12:12-05:00November 26, 2020|Healthcare workers, Media Releases|

New study to determine how many Canadians have been infected with SARS-CoV-2

Canada’s COVID-19 Immunity Task Force (CITF) is supporting a new study to identify how many Canadians have been previously infected with SARS-CoV-2, the virus that causes COVID-19. The project, conducted by Statistics Canada, will be the first to use a nationally representative sample to reflect COVID-19 seroprevalence right across Canada at national, provincial, and [...]

2021-02-26T10:37:32-05:00November 9, 2020|Media Releases|

Canada’s COVID-19 Immunity Task Force funds national study looking at seroprevalence of COVID-19 antibodies among high-risk populations

The Government of Canada is investing $1.9 million through Canada’s COVID-19 Immunity Task Force (CITF) to fund a Canadian Partnership for Tomorrow’s Health (CanPath) study looking at COVID-19 seroprevalence across Canada, with a particular focus on certain populations that are at higher risk of infection.  CanPath is a national population health research platform that follows the health of 330,000 Canadians (or [...]

2021-02-26T10:39:15-05:00October 28, 2020|Media Releases|

Study underway in Montreal to estimate how many children and teens have been infected with SARS-CoV-2

Today, Canada’s COVID-19 Immunity Task Force (CITF) announces its support for a research project that will estimate how many children and teens in Montreal have been infected with SARS-CoV-2, the virus that causes COVID-19. This $720,000 investment will allow us to better understand how much virus transmission has occurred to children and teens, and [...]

2021-02-26T10:40:25-05:00October 20, 2020|Media Releases|
Go to Top